PE20191817A1 - Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) - Google Patents
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)Info
- Publication number
- PE20191817A1 PE20191817A1 PE2019002310A PE2019002310A PE20191817A1 PE 20191817 A1 PE20191817 A1 PE 20191817A1 PE 2019002310 A PE2019002310 A PE 2019002310A PE 2019002310 A PE2019002310 A PE 2019002310A PE 20191817 A1 PE20191817 A1 PE 20191817A1
- Authority
- PE
- Peru
- Prior art keywords
- irak4
- interleukin
- inhibitors
- kinase
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Referido a un compuesto de formula I, en donde X es CR4 o N; Y es CR5 o N; o una sal o un profarmaco del mismo. Un compuesto preferido es 3-(((2S,3S)-3-etil-4,4-difluoro-5-oxopirrolidin-2-il)metoxi)-5-metoxitieno[3,2-b] piridin-6-carboxamida. Estos compuestos de tienopiridinas y benzotiofenos son inhibidores de cinasa 4 asociada al receptor de interleucina 1 (IRAK4). Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto su uso para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias, o para el tratamiento contra el cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191817A1 true PE20191817A1 (es) | 2019-12-27 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002310A PE20191817A1 (es) | 2017-05-11 | 2018-05-10 | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10829496B2 (es) |
| EP (1) | EP3621960B1 (es) |
| JP (1) | JP7154229B2 (es) |
| KR (1) | KR102604900B1 (es) |
| CN (1) | CN110612298B (es) |
| AR (1) | AR111689A1 (es) |
| AU (1) | AU2018265130B2 (es) |
| BR (1) | BR112019023290A2 (es) |
| CA (1) | CA3062602A1 (es) |
| CL (1) | CL2019003198A1 (es) |
| CO (1) | CO2019012494A2 (es) |
| CY (1) | CY1124552T1 (es) |
| DK (1) | DK3621960T3 (es) |
| EA (1) | EA039189B1 (es) |
| ES (1) | ES2889926T3 (es) |
| HR (1) | HRP20211583T1 (es) |
| HU (1) | HUE056493T2 (es) |
| IL (1) | IL270494B (es) |
| LT (1) | LT3621960T (es) |
| MX (1) | MX2019012929A (es) |
| PE (1) | PE20191817A1 (es) |
| PL (1) | PL3621960T3 (es) |
| PT (1) | PT3621960T (es) |
| RS (1) | RS62430B1 (es) |
| SI (1) | SI3621960T1 (es) |
| TW (1) | TW201900640A (es) |
| WO (1) | WO2018209012A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| AU2018396142A1 (en) | 2017-12-26 | 2020-07-16 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND THEIR USES |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| CN114174304B (zh) * | 2019-07-23 | 2024-05-17 | 百时美施贵宝公司 | 可用作irak4抑制剂的噻吩并吡啶基化合物和噻唑并吡啶基化合物 |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| JP4541695B2 (ja) | 2001-06-15 | 2010-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| JP4529685B2 (ja) | 2002-06-28 | 2010-08-25 | アステラス製薬株式会社 | ジアミノピリミジンカルボキサミド誘導体 |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| CN101171052A (zh) | 2005-03-09 | 2008-04-30 | 先灵公司 | 抑制ksp驱动蛋白活性的化合物 |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| CA2636242A1 (en) | 2006-01-30 | 2008-05-29 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
| AU2008258508A1 (en) | 2007-06-08 | 2008-12-11 | Bayer Cropscience Ag | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| US20110230467A1 (en) | 2008-11-21 | 2011-09-22 | Astellas Pharma Inc. | 4,6-diaminonicotinamide compound |
| BRPI0920966B1 (pt) | 2008-11-28 | 2022-03-03 | Kowa Company Ltd | Derivado de piridina-3-carboxiamida, seu uso, inibidor de jak3 e composição farmacêutica |
| WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| ES2444777T3 (es) | 2009-06-12 | 2014-02-26 | Bristol-Myers Squibb Company | Compuestos de nicotinamida útiles como moduladores de quinasas |
| NZ598455A (en) | 2009-09-03 | 2014-03-28 | Allergan Inc | Compounds as tyrosine kinase modulators |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| CN102971304A (zh) | 2010-02-01 | 2013-03-13 | 日本化学医药株式会社 | Gpr119激动剂 |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| MX2013012588A (es) | 2011-04-29 | 2014-05-20 | Icahn School Med Mount Sinai | Inhibidores de cinasa. |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| EP2802579B1 (en) | 2012-01-13 | 2016-04-13 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| EP2802576B1 (en) * | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| JP6204484B2 (ja) | 2012-11-08 | 2017-09-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物 |
| ES2616812T3 (es) * | 2012-11-08 | 2017-06-14 | Bristol-Myers Squibb Company | Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa |
| BR112015010244A8 (pt) | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| GEP20186887B (en) | 2014-04-04 | 2018-08-27 | Pfizer | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| US10040802B2 (en) * | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of IRAK4 activity |
| EP3268367B8 (en) * | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| TW201713663A (zh) | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| US10294229B2 (en) | 2015-06-24 | 2019-05-21 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| CN107949559B (zh) | 2015-08-27 | 2020-12-11 | 辉瑞公司 | 作为irak4调节剂的双环稠合杂芳基或芳基化合物 |
-
2018
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en unknown
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active IP Right Grant
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
-
2019
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3621960T (lt) | 2021-10-11 |
| WO2018209012A1 (en) | 2018-11-15 |
| PL3621960T3 (pl) | 2021-11-08 |
| AU2018265130A1 (en) | 2020-01-02 |
| DK3621960T3 (da) | 2021-09-27 |
| JP7154229B2 (ja) | 2022-10-17 |
| CA3062602A1 (en) | 2018-11-15 |
| US20200062777A1 (en) | 2020-02-27 |
| HRP20211583T1 (hr) | 2022-01-07 |
| IL270494B (en) | 2022-04-01 |
| ES2889926T3 (es) | 2022-01-14 |
| SI3621960T1 (sl) | 2021-11-30 |
| EP3621960A1 (en) | 2020-03-18 |
| EP3621960B1 (en) | 2021-08-04 |
| CY1124552T1 (el) | 2022-07-22 |
| BR112019023290A2 (pt) | 2020-06-16 |
| CO2019012494A2 (es) | 2020-01-17 |
| CN110612298A (zh) | 2019-12-24 |
| TW201900640A (zh) | 2019-01-01 |
| US10829496B2 (en) | 2020-11-10 |
| MX2019012929A (es) | 2020-01-14 |
| KR102604900B1 (ko) | 2023-11-21 |
| PT3621960T (pt) | 2021-09-16 |
| AR111689A1 (es) | 2019-08-07 |
| HUE056493T2 (hu) | 2022-02-28 |
| JP2020519596A (ja) | 2020-07-02 |
| EA201992674A1 (ru) | 2020-04-06 |
| RS62430B1 (sr) | 2021-11-30 |
| CN110612298B (zh) | 2023-05-05 |
| KR20200004871A (ko) | 2020-01-14 |
| AU2018265130B2 (en) | 2022-03-24 |
| CL2019003198A1 (es) | 2020-03-20 |
| EA039189B1 (ru) | 2021-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191817A1 (es) | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
| CO2020013865A2 (es) | Análogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| PH12020500485A1 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| MX2019013031A (es) | Análogos de rapamicina como inhibidores de mtor. | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| PE20091720A1 (es) | Compuestos de benzopirano y benzoxepina como inhibidores de pi3k | |
| PE20151939A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| EA201592182A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| UY36708A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| BR112018010107A2 (pt) | composição farmacêutica para o tratamento ou prevenção de nash | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين |